Literature DB >> 2405632

Evaluating diagnostic tests with imperfect standards.

P N Valenstein1.   

Abstract

New diagnostic tests frequently are evaluated against gold standards that are assumed to classify patients with unerring accuracy according to the presence or absence of disease. In practice, gold standards rarely are perfect predictors of disease and tend to misclassify a small number of patients. When an imperfect standard is used to evaluate a diagnostic test, many commonly used measures of test performance are distorted. It is not widely appreciated that these distortions occur in predictable directions and that they may be of considerable magnitude, even when the gold standard has a high degree of accuracy. The diagnostic powers of clinical tests will be more accurately reported if consideration is given to the types of biases that result from the use of imperfect standards. Several different approaches may be used to minimize these distortions when evaluating new tests.

Entities:  

Mesh:

Year:  1990        PMID: 2405632     DOI: 10.1093/ajcp/93.2.252

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  38 in total

Review 1.  Systematic review of near patient test evaluations in primary care.

Authors:  B C Delaney; C J Hyde; R J McManus; S Wilson; D A Fitzmaurice; S Jowett; R Tobias; G H Thorpe; F D Hobbs
Journal:  BMJ       Date:  1999-09-25

Review 2.  The validation of screening tests: meet the new screen same as the old screen?

Authors:  Blase Gambino
Journal:  J Gambl Stud       Date:  2012-12

Review 3.  Validation of laboratory-developed molecular assays for infectious diseases.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

Review 5.  The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests.

Authors:  Behrouz Kassaï; Nirav R Shah; Alain Leizorovicza; Michel Cucherat; Francois Gueyffier; Jean-Pierre Boissel
Journal:  J Clin Epidemiol       Date:  2005-10       Impact factor: 6.437

6.  Data mining in pharmacovigilance: lessons from phantom ships.

Authors:  Manfred Hauben; Lester Reich; Eugène P Van Puijenbroek; Charles M Gerrits; Vaishali K Patadia
Journal:  Eur J Clin Pharmacol       Date:  2006-08-03       Impact factor: 2.953

7.  Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis.

Authors:  Andrew L Baughman; Kristine M Bisgard; Margaret M Cortese; William W Thompson; Gary N Sanden; Peter M Strebel
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

8.  Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis.

Authors:  W W Reed; G S Byrd; R H Gates; R S Howard; M J Weaver
Journal:  West J Med       Date:  1996-10

10.  Data-Driven Prediction of Beneficial Drug Combinations in Spontaneous Reporting Systems.

Authors:  Ying Li; Ping Zhang; Zhaonan Sun; Jianying Hu
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.